Organovo Holdings ( (ONVO) ) just unveiled an update.

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

Organovo Holdings (NASDAQ:ONVO), Inc., a biotechnology firm specializing in biological products, has announced an expansion of its equity incentive plan, following approval from its stockholders.

Organovo Holdings ( (ONVO)) just unveiled an update. At its 2024 Annual Meeting, Organovo Holdings, Inc. secured stockholder approval for several key proposals, including an amendment to its 2022 ...

Organovo Holdings (NASDAQ:ONVO), Inc., a biotechnology firm specializing in biological products, has announced an expansion of its equity incentive plan, following approval from its stockholders.

Organovo (ONVO) announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured ...

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology company specializing in novel treatments for inflammatory bowel disease and other conditions, announced significant findings from ...

Shares of ONVO stock opened at $0.38 on Tuesday. Organovo has a fifty-two week low of $0.32 and a fifty-two week high of $1.74. The firm has a market cap of $5.84 million, a P/E ratio of -0.36 and a ...